2020
DOI: 10.1002/jcp.30010
|View full text |Cite
|
Sign up to set email alerts
|

RPL41 sensitizes retinoblastoma cells to chemotherapeutic drugs via ATF4 degradation

Abstract: Retinoblastoma is the most common intraocular cancer with metastatic potential affecting infants and children. Although chemotherapy is available for retinoblastoma, side effects and drug resistance are frequent. Rpl41, encoding ribosomal protein L41 (RPL41), has been identified as a tumor suppressor gene, and its targeted degradation of activating transcription factor 4 (ATF4) produces an antitumor effect. The goal of the present study is to provide experimental evidence for the clinical application of a smal… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 9 publications
(3 citation statements)
references
References 42 publications
0
3
0
Order By: Relevance
“…Recently, activity of human eL41 outside of its ribosomal function was discovered. Human eL41 functioned as a cell-penetrating peptide, interacting with ATF4 and targeting it to the cytoplasmic proteasome for degradation ( 70–72 ). We consider bS22 as a structure-functional homologue of eL41 and therefore investigated if free bS22 also has functions outside the ribosome.…”
Section: Resultsmentioning
confidence: 99%
“…Recently, activity of human eL41 outside of its ribosomal function was discovered. Human eL41 functioned as a cell-penetrating peptide, interacting with ATF4 and targeting it to the cytoplasmic proteasome for degradation ( 70–72 ). We consider bS22 as a structure-functional homologue of eL41 and therefore investigated if free bS22 also has functions outside the ribosome.…”
Section: Resultsmentioning
confidence: 99%
“…Construction, culture and transfection of VCR-resistant RB cell line RB cell lines (Y79, WERI-Rb-1, SO-Rb50, and SO-Rb70) were obtained from National Infrastructure of Cell Line Resource (www.cellresource), and human retinal astrocyte (HRA) was purchased from ZQXZ Biotech (Shanghai, China). All the cells were cultured in RPMI-1640 medium (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany) containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin-glutamine (100X, Gibco, Grand Island, NY, USA) at 37℃ with 5% CO 2 [21]. The VCR-resistant RB cell line was constructed by E-test, lasting for 9 months, and the concentration of VCR ranged from 75 µg/mL to 600 µg/mL.…”
Section: Clinical Samplementioning
confidence: 99%
“…1 , 2 However, there are limitations for the chemotherapy of RB, such as drug resistance and side effects. 3 Therefore, further identification of biomarkers of RB progression will be helpful for developing new molecular prognostic indicators and novel treatment strategies.…”
Section: Introductionmentioning
confidence: 99%